anurajms/meta_analysis huggingface dataset:
outcomes:
Parenteral anticoagulation in ambulatory patients with cancer
1. Thrombocytopenia 2. All Cause Mortality 3. Impaired quality of life 4. Minor Bleed 5. Venous Thrombosis 6. Major Bleed
outcomes:
Prophylactic chemotherapy for hydatidiform mole to prevent gestational trophoblastic neoplasia
1. Gestational Trophoblastic Neoplasia
outcomes:
Retinoic acid postconsolidation therapy for high‐risk neuroblastoma patients treated with autologous haematopoietic stem cell transplantation
1. Overall Survival 2. Event-Free Survival 3. Progression-Free Survival 4. Quality of Life 5. Death 6. Drug toxicity
outcomes:
Home‐based multidimensional survivorship programmes for breast cancer survivors
1. Fatigue 2. Depression 3. Anxiety 4. Health-Related Quality of Life
outcomes:
Chemoradiotherapy versus chemoradiotherapy plus surgery for esophageal cancer
1. Relapse 2. Overall Survival 3. Quality of Life 4. Death 5. Dysphagia 6. Spitzer Quality Of Life Index
outcomes:
Procarbazine, lomustine and vincristine for recurrent high‐grade glioma
1. Death
outcomes:
Non‐steroidal anti‐inflammatory drugs (NSAIDs) for cancer‐related pain in children and adolescents
1. Pain Relief 2. Patient's Global Evaluation 3. Patient-Reported Outcome
outcomes:
Opioids for cancer‐related pain in children and adolescents
1. Pain 2. Patient Global Impression of Change 3. Pain Relief 4. Patient-Reported Outcome
outcomes:
Psychosocial interventions for fatigue during cancer treatment with palliative intent
1. Cognitive function 2. Social Interaction 3. Fatigue 4. Emotional State 5. Functional ability 6. Adverse Event
outcomes:
Oral nonsteroidal anti‐inflammatory drugs (NSAIDs) for cancer pain in adults
1. Withdrawn From Research Study 2. Serious Adverse Event 3. Death 4. Patient Global Impression of Improvement 5. Mild Pain 6. Adverse Event 7. Clinical Improvement
outcomes:
Oral paracetamol (acetaminophen) for cancer pain
1. Serious Adverse Event 2. Drug Therapy 3. Quality of Life 4. Patient Global Impression of Improvement 5. Adverse Event 6. Mild Pain 7. Pain Relief 8. Patient-Reported Outcome
outcomes:
Corticosteroids for adult patients with advanced cancer who have nausea and vomiting (not related to chemotherapy, radiotherapy, or surgery)
1. Vomiting 2. Quality of Life 3. Nausea 4. Adverse Event 5. Patient Satisfaction
outcomes:
Retroperitoneal drainage versus no drainage after pelvic lymphadenectomy for the prevention of lymphocyst formation in women with gynaecological malignancies
1. Lymphocytes 2. Pelvic Infection 3. Febrile Disorder
outcomes:
Ketamine as an adjuvant to opioids for cancer pain
1. Pain 2. Visual Analog Scale 3. Verbal Rating Scale 4. Adverse Event
outcomes:
Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer
1. Metastatic Colorectal Cancer 2. Neutropenic Disorder 3. Overall Survival 4. Progression-Free Survival 5. Quality of Life 6. Death 7. Diarrhoea 8. Skin Rash 9. Drug toxicity 10. Therapeutic Response
outcomes:
Platinum‐containing regimens for metastatic breast cancer
1. Disease Progression 2. Death
outcomes:
Early palliative care for adults with advanced cancer
1. Pain 2. Quality of Life 3. Edmonton symptom assessment system 4. Depression 5. Death
outcomes:
Focal laser treatment in addition to chemotherapy for retinoblastoma
1. Recurrent Tumor
outcomes:
Empirical antibiotics targeting gram‐positive bacteria for the treatment of febrile neutropenic patients with cancer
1. Treatment Failure 2. Death 3. Adverse Event
outcomes:
Drug therapy for symptoms associated with anxiety in adult palliative care patients
1. Anxiety
outcomes:
Tramadol with or without paracetamol (acetaminophen) for cancer pain
1. Withdrawn From Research Study 2. Quality of Life 3. Death 4. Patient Global Impression of Improvement 5. Mild Pain 6. Adverse Event 7. Pain Relief
outcomes:
Immunotherapy for metastatic renal cell carcinoma
1. Overall Survival 2. Quality of Life 3. Death 4. Adverse Event 5. Clinical Improvement
outcomes:
Partial nephrectomy versus radical nephrectomy for clinical localised renal masses
1. Serious Adverse Event 2. Recurrent Tumor 3. Renal cell carcinoma 4. Quality of Life 5. Death 6. Haemodialysis 7. Time-to-Event
outcomes:
Alvimopan for recovery of bowel function after radical cystectomy
1. Bowel Action 2. Solid Food 3. Hospital discharge 4. Serious Adverse Event 5. Cardiovascular Event 6. Readmission 7. Time-to-Event
outcomes:
Biopsy versus resection for the management of low‐grade gliomas
1. Death
outcomes:
Autologous hematopoietic stem cell transplantation following high‐dose chemotherapy for nonrhabdomyosarcoma soft tissue sarcomas
1. Death
outcomes:
Online support groups for women with breast cancer
1. Emotional Distress 2. Uncertain Behavior 3. Quality of Life 4. Depression 5. Anxiety
outcomes:
Intravesical Bacillus Calmette‐Guérin with interferon‐alpha versus intravesical Bacillus Calmette‐Guérin for treating non‐muscle‐invasive bladder cancer
1. Superficial Bladder Cancer 2. Recurrent Tumor 3. Quality of Life 4. Death 5. Withdrawal Due To Adverse Events 6. Tumor Progression 7. Time-to-Event
outcomes:
External beam radiotherapy for unresectable hepatocellular carcinoma
1. All Cause Mortality 2. Serious Adverse Event 3. Health-Related Quality of Life
outcomes:
Interventions for raising breast cancer awareness in women
1. Finding Related To Development Of The Breasts 2. Breast Signs And Symptoms
outcomes:
Methadone for cancer pain
1. Mild Pain 2. Adverse Event 3. Pain Relief 4. Pain Intensity
outcomes:
Second‐line systemic therapy for metastatic colorectal cancer
1. Serious Adverse Event 2. Disease Progression 3. Overall Survival 4. Progression-Free Survival 5. Colorectal Cancer 6. Death 7. Therapeutic Response
outcomes:
Immediate referral to colposcopy versus cytological surveillance for minor cervical cytological abnormalities in the absence of HPV test
1. Cervical Intraepithelial Neoplasia
outcomes:
Antibiotics for infection prevention after excision of the cervical transformation zone
1. Infection 2. Inflammation Of Cervix 3. Systemic Antibacterial Therapy 4. Vaginal Bleeding 5. Lower Abdominal Pain 6. Multi-antibiotic Resistance 7. Vaginal Discharge Problem 8. Q Fever 9. Pelvic Inflammatory Disease 10. Complication 11. Endometritis
outcomes:
Dietary fibre for the prevention of recurrent colorectal adenomas and carcinomas
1. Colon Adenomatous Polyp 2. Colorectal Cancer
outcomes:
Axillary treatment for operable primary breast cancer
1. Neoplasm Of Axilla 2. Surgical complication 3. Impairment 4. Decreased Range Of Shoulder Movement 5. Paresthesia 6. Recurrent Cancer 7. All Cause Mortality 8. Recurrent breast cancer 9. Pain 10. Lymphedema 11. Reduced Movement Of Arm 12. Overall Survival 13. Death 14. Complication 15. Numbness
outcomes:
Fulvestrant for hormone‐sensitive metastatic breast cancer
1. Progression-Free Survival
outcomes:
Yoga for improving health‐related quality of life, mental health and cancer‐related symptoms in women diagnosed with breast cancer
1. Depression 2. Fatigue 3. Anxiety 4. Sleep disturbances 5. Health-Related Quality of Life
outcomes:
Minimally invasive surgery versus radiotherapy/chemoradiotherapy for small‐volume primary oropharyngeal carcinoma
1. Gastrostomy 2. Death 3. Recurrence free survival 4. Tracheostomy 5. Dysphagia 6. Tumor Progression 7. Local Control Of Neoplasm
outcomes:
Nipple‐ and areola‐sparing mastectomy for the treatment of breast cancer
1. Infection 2. Overall Survival 3. Skin Necrosis 4. Complication 5. Locally Recurrent Breast Cancer
outcomes:
Educational interventions for the management of cancer‐related fatigue in adults
1. Fatigue
outcomes:
Adjuvant platinum‐based chemotherapy for early stage cervical cancer
1. Platelet Toxicity 2. Recurrence free survival
outcomes:
Benzodiazepines for the relief of breathlessness in advanced malignant and non‐malignant diseases in adults
1. Borg Scale 2. Dyspnea 3. Chronic Respiratory Disease Questionnaire 4. Visual Analog Scale
outcomes:
Neuromuscular electrical stimulation for muscle weakness in adults with advanced disease
1. Oxygen 2. Serious Adverse Event 3. Walking Distance Test 4. Adverse Event 5. Muscle Strength 6. Muscle Mass
outcomes:
Laparoscopy versus laparotomy for FIGO stage I ovarian cancer
1. Death
outcomes:
Exercise for women receiving adjuvant therapy for breast cancer
1. Cognitive function 2. Lymphedema 3. Physical Activity Level 4. Quality of Life 5. Depression 6. Fatigue
outcomes:
Therapeutic exercises for affecting post‐treatment swallowing in people treated for advanced‐stage head and neck cancers
1. Pneumonia 2. Lower Respiratory Tract Infection 3. Yeast Infection 4. Aspiration 5. Aspiration Pneumonia 6. Oropharyngeal Dysphagia 7. Dehydration 8. Adverse Event 9. Swallowing Finding 10. Weight Loss 11. Mucosal inflammation 12. Complication 13. Dysphagia
outcomes:
Nutritional interventions for survivors of childhood cancer
1. Nutritional Finding
outcomes:
Non‐pharmacological interventions for cognitive impairment due to systemic cancer treatment
1. Cognitive function 2. Psychological Finding 3. General well-being
outcomes:
Interventions for treating oral leukoplakia to prevent oral cancer
1. Malignant Tumor Of Oral Cavity
outcomes:
Sun protection for preventing basal cell and squamous cell skin cancers
1. Squamous Cell Carcinoma Of Skin 2. Basal Cell Carcinoma Of Skin
outcomes:
Molecular‐targeted first‐line therapy for advanced gastric cancer
1. European Organization For Research And Treatment Of Cancer - Quality Of Life Questionnaire 2. Serious Adverse Event 3. Disease Progression 4. Overall Survival 5. Progression-Free Survival 6. Adverse Event 7. Therapeutic Response
outcomes:
Pain relief for women with cervical intraepithelial neoplasia undergoing colposcopy treatment
1. Pain
outcomes:
Hypofractionated radiation therapy for early breast cancer
1. Simple mastectomy 2. Event-Free Survival 3. Death 4. Toxicity Due To Radiotherapy 5. Finding Of Appearance Of Breast 6. Recurrence free survival 7. Cosmetics 8. Breast Cancer 9. Survival
outcomes:
Intracystic bleomycin for cystic craniopharyngiomas in children
1. Headache 2. Cranial Nerve 3-paralysis 3. Vomiting 4. Event-Free Survival 5. Overall Survival 6. Neurological Finding 7. Death 8. Craniopharyngioma 9. Adverse Event 10. Fever
outcomes:
Luteinising hormone releasing hormone (LHRH) agonists for the treatment of relapsed epithelial ovarian cancer
1. Neutropenic Disorder 2. Neurotoxicity 3. Alopecia 4. Nausea And Vomiting 5. Overall Survival 6. Progression-Free Survival 7. Death
outcomes:
Radiotherapy for diffuse brainstem glioma in children and young adults
1. Overall Survival 2. Progression-Free Survival 3. Event-Free Survival 4. Neurological Finding 5. Quality of Life 6. Death 7. Radiologic Finding 8. Drug toxicity
outcomes:
Massage with or without aromatherapy for symptom relief in people with cancer
1. Visual Analog Pain Scale 2. Quality of Life 3. Depression 4. Anxiety 5. Verbal Rating Scale 6. Pain Relief 7. Pain Intensity
outcomes:
Follow‐up strategies for women treated for early breast cancer
1. Disease-Free Survival 2. Overall Survival 3. Quality of Life 4. Death 5. Health-Related Quality of Life
outcomes:
High‐dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with early poor prognosis breast cancer
1. Recurrent breast cancer 2. Overall Survival 3. Event-Free Survival 4. Death
outcomes:
Different types of implants for reconstructive breast surgery
1. Reconstruction Of Breast With Immediate Insertion Of Breast Prosthesis 2. Breast Implantation 3. Quality of Life 4. Complication 5. Capsular Breast Contracture Of Breast Implant 6. Patient Satisfaction
outcomes:
Stents for the prevention of pancreatic fistula following pancreaticoduodenectomy
1. Delayed Gastric Emptying 2. Abdominal abscess 3. Pancreatic Fistula 4. Death 5. Wound Infection
outcomes:
Non‐surgical interventions for late rectal problems (proctopathy) of radiotherapy in people who have received radiotherapy to the pelvis
1. Bowel Action 2. Tenesmus 3. Pain 4. Urgent Desire For Stool 5. Dysfunction Of Sphincter Of Oddi 6. Haemorrhage
outcomes:
Low bacterial diet versus control diet to prevent infection in cancer patients treated with chemotherapy causing episodes of neutropenia
1. Infection 2. Death
outcomes:
Oral morphine for cancer pain
1. Pain Intensity Rating Scale 2. Pain 3. Visual Analog Scale 4. Pain Relief 5. Patient-Reported Outcome
outcomes:
Chromoscopy versus conventional endoscopy for the detection of polyps in the colon and rectum
1. Tubular Adenoma 2. Number of lesions 3. Adverse Event 4. Polyp
outcomes:
Ganoderma lucidum (Reishi mushroom) for cancer treatment
1. Death 2. Therapeutic Response
outcomes:
Laparoscopic versus open distal pancreatectomy for pancreatic cancer
1. Serious Adverse Event 2. Disease Recurrence 3. Pancreatic Fistula 4. Death
outcomes:
Laparoscopic versus open gastrectomy for gastric cancer
1. Serious Adverse Event 2. Blood Transfusion 3. Death 4. Health-Related Quality of Life
outcomes:
Opioids for the palliation of refractory breathlessness in adults with advanced disease and terminal illness
1. Exercise Tolerance Finding 2. Borg Scale 3. Dyspnea 4. Vomiting 5. Quality of Life 6. Visual Analog Scale 7. Nausea 8. Sleepiness 9. Constipation
outcomes:
Laparoscopic versus open transhiatal oesophagectomy for oesophageal cancer
1. Serious Adverse Event 2. Blood Transfusion 3. Anastomotic stenosis 4. Death
outcomes:
Physical exercise training interventions for children and young adults during and after treatment for childhood cancer
1. Body Mass Index 2. Physical fitness 3. Bone Density 4. Physical Activity Level 5. Quality of Life 6. Fatigue 7. Range Of Ankle Flexion
outcomes:
Non‐surgical versus surgical treatment for oesophageal cancer
1. All Cause Mortality 2. Oesophageal Carcinoma Recurrent 3. Serious Adverse Event 4. Length Of Stay 5. Dysphagia 6. Health-Related Quality of Life
outcomes:
Very early discharge versus early discharge versus non‐early discharge in children with cancer and febrile neutropenia
1. Costs and Cost Analysis 2. Treatment Failure 3. Quality of Life 4. Death 5. Hospitalization 6. Antibiotic Therapy
outcomes:
Pylorus‐preserving pancreaticoduodenectomy (pp Whipple) versus pancreaticoduodenectomy (classic Whipple) for surgical treatment of periampullary and pancreatic carcinoma
1. Delayed Gastric Emptying 2. Death 3. Red Blood Cell Transfusion 4. Haemorrhage
outcomes:
Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression‐free survival in patients with advanced and/or metastatic colorectal cancer
1. Disease Progression 2. Overall Survival 3. Progression-Free Survival 4. Diarrhea 5. Death 6. Nausea 7. Time-to-Event
outcomes:
End‐of‐life care pathways for improving outcomes in caring for the dying
1. Hospital Anxiety And Depression Scale 2. Quality of Life 3. Adverse Event 4. Symptom control therapy
outcomes:
Percutaneous endoscopic gastrostomy versus percutaneous radiological gastrostomy for swallowing disturbances
1. Death
outcomes:
Antiemetic medication for prevention and treatment of chemotherapy‐induced nausea and vomiting in childhood
1. Vomiting 2. Quality of Life 3. Nausea 4. Adverse Event
outcomes:
Effectiveness of tranexamic acid in reducing blood loss during cytoreductive surgery for advanced ovarian cancer
1. Repeat surgery 2. Red Blood Cell Transfusion 3. Readmission 4. Plasma transfusion 5. Haemorrhage 6. Thromboembolic Event
outcomes:
Chemotherapy for resistant or recurrent gestational trophoblastic neoplasia
1. Treatment Failure 2. Death 3. Complete response
outcomes:
Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer
1. Death
outcomes:
Interval debulking surgery for advanced epithelial ovarian cancer
1. Death
outcomes:
Localization techniques for guided surgical excision of non‐palpable breast lesions
1. Excision - Clear Margin 2. Treatment Success 3. Excision Of Lesion Of Breast 4. Lesion Of Breast
outcomes:
Adjuvant (post‐surgery) chemotherapy for early stage epithelial ovarian cancer
1. Death 2. No Evidence Of Neoplasm
outcomes:
Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy
1. Death 2. Local Control Of Neoplasm
outcomes:
Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy
1. Nausea And Vomiting
outcomes:
Stapler versus scalpel resection followed by hand‐sewn closure of the pancreatic remnant for distal pancreatectomy
1. Operation time 2. Duration Of Surgery 3. Death 4. Postoperative Fistula
outcomes:
Levomepromazine for nausea and vomiting in palliative care
1. Vomiting 2. Nausea 3. Patient-Reported Outcome
outcomes:
Haloperidol for the treatment of nausea and vomiting in palliative care patients
1. Vomiting 2. Nausea 3. Patient-Reported Outcome
outcomes:
Chemotherapy for advanced non‐small cell lung cancer in the elderly population
1. Thrombocytopenia 2. Objective Response Rate 3. Neutropenic Disorder 4. Peripheral Nerve Disease 5. Anemia 6. Overall Survival 7. Progression-Free Survival 8. Quality of Life
outcomes:
Acupuncture for cancer pain in adults
1. Pain Intensity 2. Patient-Reported Outcome
outcomes:
High‐dose chemotherapy and autologous haematopoietic stem cell rescue for children with high‐risk neuroblastoma
1. Event-Free Survival 2. Overall Survival 3. Death
outcomes:
Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients
1. Event-Free Survival 2. Overall Survival 3. Death 4. Therapeutic Response
outcomes:
Oral tapentadol for cancer pain
1. Pain 2. Patient Global Impression of Improvement 3. Mild Pain 4. Pain Relief
outcomes:
Nutritional support in children and young people with cancer undergoing chemotherapy
1. Body Mass Index 2. Serum Glucose 3. Body Fat Finding 4. Body weight 5. Dyslipidemia 6. Nausea 7. Finding Of Upper Limb 8. Infection 9. Ammonia 10. Protein Total 11. Serum Albumin 12. Energy 13. Vomiting 14. Prealbumin 15. Mucosal inflammation 16. Body Height 17. Diarrhoea
outcomes:
Multidisciplinary rehabilitation after primary brain tumour treatment
1. Disability 2. Perceived Impact of Problem Profile 3. Costs and Cost Analysis 4. Serious Adverse Event 5. Cancer Rehabilitation Evaluation System-Short Form 6. Functional Independence Measure 7. Impairment 8. Quality of Life 9. Depression Anxiety Scale
outcomes:
Spinal cord stimulation for cancer‐related pain in adults
1. Depression 2. Anxiety 3. Functional ability 4. Health-Related Quality of Life 5. Pain Relief
outcomes:
Taxane‐containing regimens for metastatic breast cancer
1. Disease Progression 2. Overall Survival 3. Death 4. Breast Cancer 5. Time-to-Event
outcomes:
Pharmacological treatments for fatigue associated with palliative care
1. Fatigue 2. Clinical Improvement 3. Patient-Reported Outcome
outcomes:
Percutaneous endoscopic gastrostomy versus nasogastric tube feeding for adults with swallowing disturbances
1. Pneumonia 2. Treatment Failure 3. Death 4. Adverse Event
outcomes:
Rapid COJEC versus standard induction therapies for high‐risk neuroblastoma
1. Overall Survival 2. Event-Free Survival 3. Progression-Free Survival 4. Death 5. Adverse Event 6. Therapeutic Response 7. Drug toxicity
outcomes:
Interventions for cough in cancer
1. Frequency of symptom 2. Cough 3. Clinical Improvement
outcomes:
Sentinel lymph node biopsy followed by lymph node dissection for localised primary cutaneous melanoma
1. Death 2. Adverse Event
outcomes:
Laxatives for the management of constipation in people receiving palliative care
1. Laxation response 2. Bristol Stool Form Scale 3. Frequency Of Defecation 4. Adverse Event
outcomes:
Laetrile treatment for cancer
1. Death 2. Adverse Event 3. Therapeutic Response
outcomes:
Buprenorphine for treating cancer pain
1. Pain 2. Adverse Event 3. Pain Relief 4. Patient's Global Evaluation 5. Pain Intensity 6. Patient Satisfaction 7. Patient-Reported Outcome
outcomes:
Chewing gum for postoperative recovery of gastrointestinal function
1. Bowel Action 2. Costs and Cost Analysis 3. Complication 4. Length Of Stay 5. Time-to-Event 6. Finding Of Flatus 7. Tolerance Related Finding
outcomes:
Conservative interventions for preventing clinically detectable upper‐limb lymphoedema in patients who are at risk of developing lymphoedema after breast cancer therapy
1. Shoulder Joint - Range Of Movement 2. Lymphedema Of Upper Limb
outcomes:
Percutaneous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma
1. Death
outcomes:
Palliative radiotherapy regimens for patients with thoracic symptoms from non‐small cell lung cancer
1. Oesophagitis 2. Disorder Of Thorax 3. Radiation Pneumonitis 4. Overall Survival 5. Radiation myelopathy
outcomes:
Dance/movement therapy for improving psychological and physical outcomes in cancer patients
1. General physical health deterioration 2. Body Image Finding 3. Depression 4. Fatigue 5. Feeling Angry 6. Anxiety 7. Feeling Relief 8. Stress
outcomes:
Follow‐up strategies after treatment (large loop excision of the transformation zone (LLETZ)) for cervical intraepithelial neoplasia (CIN): Impact of human papillomavirus (HPV) test
1. Disease Recurrence
outcomes:
Minimally invasive surgery versus open surgery for the treatment of solid abdominal and thoracic neoplasms in children
1. Overall Survival 2. Event-Free Survival 3. Death 4. Metastasis 5. Recurrent Cancer
outcomes:
Chemotherapy for children with medulloblastoma
1. Disease Recurrence 2. Disease Progression 3. Medulloblastoma 4. Death 5. Time-to-Event
outcomes:
Adjuvant chemotherapy after concurrent chemoradiation for locally advanced cervical cancer
1. Disease Recurrence 2. Death
outcomes:
Long‐term proton pump inhibitor (PPI) use and the development of gastric pre‐malignant lesions
1. Intestinal Metaplasia 2. Atrophy Of Corpus Callosum 3. Hyperplasia 4. Premalignant gastric lesion 5. Micronodular Adrenal Hyperplasia
outcomes:
Droperidol for treatment of nausea and vomiting in palliative care patients
1. Vomiting 2. Patient-Reported Outcome
outcomes:
Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy‐naive advanced non‐small cell lung cancer
1. Serious Adverse Event 2. Overall Survival 3. Progression-Free Survival 4. Quality of Life 5. Survival 6. Therapeutic Response
outcomes:
Colony‐stimulating factors for chemotherapy‐induced febrile neutropenia
1. Infection 2. Treatment Withdrawal 3. Duration of Symptom 4. Neutropenic Disorder 5. Death 6. Hospitalization 7. Time-to-Event 8. Fever 9. Deep Venous Thrombosis 10. Clinical Improvement
outcomes:
High dose rate versus low dose rate intracavity brachytherapy for locally advanced uterine cervix cancer
1. Distant Metastasis M1 (IV) 2. Invasive Cervical Cancer 3. Event-Free Survival 4. Overall Survival 5. Local Recurrence Of Malignant Tumor Of Cervix 6. Local Control Of Neoplasm 7. Survival
outcomes:
Codeine, alone and with paracetamol (acetaminophen), for cancer pain
1. Serious Adverse Event 2. Death 3. Withdrawal Due To Adverse Events 4. Pain Relief 5. Patient's Global Evaluation 6. Pain Intensity
outcomes:
Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer
1. Overall Survival 2. Event-Free Survival 3. Death
outcomes:
Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults
1. Kaposi's sarcoma 2. Death 3. Adverse Event 4. Therapeutic Response
outcomes:
Non‐steroidal antiandrogen monotherapy compared with luteinising hormone–releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer
1. Gynecomastia 2. Disease Progression 3. Overall Survival 4. Hot Flash In Male 5. Breast Pain
outcomes:
Impact of morphine, fentanyl, oxycodone or codeine on patient consciousness, appetite and thirst when used to treat cancer pain
1. Difficulty Drinking 2. Consciousness finding 3. Difficulty Eating
outcomes:
Surgical treatment of stage IA2 cervical cancer
1. Overall Survival 2. Death
outcomes:
Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus)
1. Overall Survival 2. Progression-Free Survival
outcomes:
Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas
1. Death
outcomes:
Adjuvant chemotherapy for advanced endometrial cancer
1. All Cause Mortality 2. Overall Survival 3. Progression-Free Survival
outcomes:
Medically assisted nutrition for adult palliative care patients
1. Quality of Life
outcomes:
Laparoscopic versus open total mesorectal excision for rectal cancer
1. Disease-Free Survival 2. Surgical Circumferential Margin Finding 3. Local recurrence 4. Overall Survival 5. Duration Of Hospital Stay 6. Lymph Nodes 7. Morbidity
outcomes:
Surgical interventions for high‐grade vulval intraepithelial neoplasia
1. Evaluating Response To Treatment 2. Disease Recurrence 3. Disease Progression
outcomes:
Surgery or radiosurgery plus whole brain radiotherapy versus surgery or radiosurgery alone for brain metastases
1. Death
outcomes:
Resection versus other treatments for locally advanced pancreatic cancer
1. Costs and Cost Analysis 2. Serious Adverse Event 3. Overall Survival 4. Quality of Life 5. Duration Of Hospital Stay
outcomes:
De‐escalation treatment protocols for human papillomavirus‐associated oropharyngeal squamous cell carcinoma
1. Cancer Treatment Related Morbidity 2. Overall Survival 3. Adverse Event
outcomes:
Exenterative surgery for recurrent gynaecological malignancies
1. Overall Survival 2. Death
outcomes:
Combination versus sequential single agent chemotherapy for metastatic breast cancer
1. Overall Survival 2. Progression-Free Survival
outcomes:
Chemotherapy versus best supportive care for extensive small cell lung cancer
1. Overall Survival
outcomes:
Post‐operative radiotherapy for ductal carcinoma in situ of the breast
1. All Cause Mortality 2. Recurrent contralateral breast cancer 3. Lung cancer 4. Pulmonary Toxicity 5. Osteoradionecrosis 6. Recurrent ipsilateral breast cancer 7. Cardiac Death 8. Metastatic Disease 9. Complication 10. Radiotherapy 11. Breast Cancer
outcomes:
Patient‐reported outcome measures for follow‐up after gynaecological cancer treatment
1. Death
outcomes:
Pegylated liposomal doxorubicin for first‐line treatment of epithelial ovarian cancer
1. Thrombocytopenia 2. Alopecia 3. Anemia 4. Overall Survival 5. Progression-Free Survival 6. Death 7. Neuropathy
outcomes:
Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients
1. Infection 2. All Cause Mortality 3. Treatment Failure 4. Death 5. Adverse Event
outcomes:
Laparoscopically assisted radical vaginal hysterectomy versus radical abdominal hysterectomy for the treatment of early cervical cancer
1. Disease-Free Survival 2. Overall Survival 3. Progression-Free Survival 4. Death
outcomes:
Perioperative nutrition interventions for women with ovarian cancer
1. Death 2. Duration Of Hospital Stay 3. Hospital Bed
outcomes:
Cervico‐thoracic or lumbar sympathectomy for neuropathic pain and complex regional pain syndrome
1. Serious Adverse Event 2. Pain 3. Visual Analog Scale 4. Death 5. Patient Global Impression of Change 6. Withdrawal Due To Adverse Events 7. Mild Pain 8. Pain Relief 9. Patient-Reported Outcome
outcomes:
Psychosocial interventions for patients with head and neck cancer
1. European Organization For Research And Treatment Of Cancer - Quality Of Life Questionnaire 2. Quality of Life
outcomes:
Maintenance chemotherapy for ovarian cancer
1. Toxicity Renal 2. Vomiting 3. Progression-Free Survival 4. Overall Survival 5. Quality of Life 6. Toxic Hepatitis 7. Diarrhea 8. Death 9. Bone marrow toxicity 10. Nausea 11. Urinary bladder toxicity 12. Mucositis Following Therapy
outcomes:
Beta‐lactam versus beta‐lactam‐aminoglycoside combination therapy in cancer patients with neutropenia
1. All Cause Mortality 2. Treatment Failure 3. Nephrotoxicity
outcomes:
Interventions for cutaneous Bowen's disease
1. Disease Recurrence 2. Finding Of Lesion
outcomes:
Interferon alpha for the adjuvant treatment of cutaneous melanoma
1. Disease-Free Survival 2. Disease Recurrence 3. Overall Survival 4. Death
outcomes:
Effectiveness and cost‐effectiveness of home palliative care services for adults with advanced illness and their caregivers
1. Costs and Cost Analysis 2. Death
outcomes:
Interferon after surgery for women with advanced (Stage II‐IV) epithelial ovarian cancer
1. Death 2. Recurrence free survival
outcomes:
Fibrin glue instillation under skin flaps to prevent seroma‐related morbidity following breast and axillary surgery
1. Postoperative Complication 2. Surgical Site Infection 3. Seroma Of Breast As Complication Of Procedure 4. Duration Of Hospital Stay 5. Adverse Event
outcomes:
Sequencing of chemotherapy and radiotherapy for early breast cancer
1. Metastic cancer 2. Death 3. Locally Recurrent Breast Cancer
outcomes:
Temozolomide for high grade glioma
1. Overall Survival 2. Death
outcomes:
Megestrol acetate for treatment of anorexia‐cachexia syndrome
1. Edema 2. Increased Appetite 3. Quality of Life 4. Death 5. Weight Gain 6. Adverse Event 7. Thromboembolic Event
outcomes:
Pre‐treatment surgical para‐aortic lymph node assessment in locally advanced cervical cancer
1. Progression-Free Survival 2. Death 3. Drug toxicity
outcomes:
Multidimensional rehabilitation programmes for adult cancer survivors
1. Self Efficacy 2. Physical fitness 3. Quality of Life 4. Depression 5. Anxiety 6. Functional ability
outcomes:
Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma
1. Overall Survival 2. Death
outcomes:
Chemotherapy for metastatic and recurrent cervical cancer
1. Overall Survival 2. Death 3. Therapeutic Response
outcomes:
Interventions for reducing anxiety in women undergoing colposcopy
1. Stai - Spielberger State-trait Anxiety Inventory 2. Anxiety
outcomes:
Chemotherapy for malignant germ cell ovarian cancer in adult patients with early stage, advanced and recurrent disease
1. Death
outcomes:
Chemotherapy and surgery versus surgery alone in non‐small cell lung cancer
1. Disease-Free Survival 2. Overall Survival
outcomes:
Topical anti‐inflammatory treatments for eczema: network meta‐analysis
1. Eczema 2. Investigator Global Assessment
outcomes:
Non‐invasive high‐frequency ventilation in newborn infants with respiratory distress
1. Chronic Lung Disease 2. Death 3. Neurodevelopmental Disorder 4. Endotracheal intubation
outcomes:
Oral killed cholera vaccines for preventing cholera
1. Cholera
outcomes:
Topical and oral steroids for otitis media with effusion (OME) in children
1. Hearing 2. Quality of Life 3. Adverse Event
outcomes:
Interventions for improving coverage of childhood immunisation in low‐ and middle‐income countries
1. Vaccine 2. Vaccination For Diphtheria, Pertussis, And Tetanus
outcomes:
Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del)
1. Forced Vital Capacity 2. Cystic Fibrosis Pulmonary Exacerbation 3. Forced Expiratory Volume 4. Quality of Life 5. Lung function test 6. Adverse Event 7. Survival 8. Time-to-Event
outcomes:
Different antibiotic treatments for group A streptococcal pharyngitis
1. Relapse 2. Clinical Resolution 3. Adverse Event
outcomes:
Ventilation tubes (grommets) for otitis media with effusion (OME) in children
1. Hearing 2. Adverse Event 3. Health-Related Quality of Life
outcomes:
Antibiotics for acute otitis media in children
1. Tympanometry Testing 2. Pain 3. Vomiting 4. Diarrhoea 5. Skin Rash 6. Allergic Reaction To Antibiotics
outcomes:
Methylxanthine for the prevention and treatment of apnea in preterm infants
1. Positive Pressure Therapy 2. Chronic Lung Disease 3. Apnea 4. Death 5. Neurodevelopmental Disorder
outcomes:
Anti‐seizure medications for neonates with seizures
1. Death 2. Seizure Free 3. Neurodevelopmental Disorder
outcomes:
Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection
1. All Cause Mortality 2. Serious Adverse Event 3. Duration Of Hospital Stay 4. Adverse Event
outcomes:
Immunomodulatory interventions for focal epilepsy
1. Seizure
outcomes:
Higher versus lower sodium intake for preterm infants
1. Growth Failure 2. Chronic Lung Disease 3. Hyponatremia 4. Hypernatraemia 5. Necrotizing Enterocolitis 6. Death 7. Neurodevelopmental Disorder
outcomes:
Superoxide dismutase for bronchopulmonary dysplasia in preterm infants
1. Bronchopulmonary Dysplasia Of Newborn 2. Death 3. Neonatal Death
outcomes:
Caffeine versus other methylxanthines for the prevention and treatment of apnea in preterm infants
1. All Cause Mortality 2. Hearing impairment 3. Visual Impairment 4. Developmental Delay 5. Cerebral Palsy 6. Gross Motor Disability
outcomes:
Psychological interventions for depression in adolescent and adult congenital heart disease
1. Depression
outcomes:
Musical and vocal interventions to improve neurodevelopmental outcomes for preterm infants
1. Psychomotor Development Impaired 2. Anxious Parent 3. Developmental Mental Disorder 4. Oxygen Saturation 5. Neurodevelopmental Delay
outcomes:
Breastfeeding or breast milk for procedural pain in neonates
1. Heart Rate 2. Pain 3. Respiratory Rate 4. Blood Pressure Alteration 5. Douleur Aigue du Nouveau-ne 6. Neonatal Infant Pain Scale 7. Finding Related Physiologic Patient State 8. Crying Infant 9. Oxygen Saturation 10. Neonatal Facial Coding System
outcomes:
Specific psychological therapies versus other therapies or no treatment for severe and enduring anorexia nervosa
1. Clinical Improvement
outcomes:
Paracetamol (acetaminophen) or non‐steroidal anti‐inflammatory drugs, alone or combined, for pain relief in acute otitis media in children
1. Pain 2. Adverse Event 3. Time-to-Event 4. Fever 5. Health Care Utilization 6. Pain Relief 7. Antibiotic Therapy
outcomes:
High flow nasal cannula for respiratory support in term infants
1. Reintubate 2. Death 3. Intubation
outcomes:
Vocabulary interventions for second language (L2) learners up to six years of age
1. Expressive L2 vocabulary 2. Receptive L2 vocabulary 3. Mean length of utterance
outcomes:
Perioperative glycaemic control for people with diabetes undergoing surgery
1. Infection 2. Death 3. Hypoglycemia
outcomes:
Probiotics to prevent necrotising enterocolitis in very preterm or very low birth weight infants
1. All Cause Mortality 2. Necrotizing Enterocolitis 3. Nosocomially Acquired Neonatal Sepsis
outcomes:
Early nasal intermittent positive pressure ventilation (NIPPV) versus early nasal continuous positive airway pressure (NCPAP) for preterm infants
1. Chronic Lung Disease 2. Pneumothorax 3. Apnea 4. Intraventricular Hemorrhage 5. Respiratory Acidosis 6. Intermittent Positive Pressure Breathing 7. Death 8. Intubation 9. Respiratory Failure 10. Oxygen Supplementation 11. Endotracheal Tube Present
outcomes:
Continuous positive airway pressure (CPAP) for apnoea of prematurity
1. Bradycardia 2. Apnea 3. Treatment Failure
outcomes:
Vedolizumab for induction and maintenance of remission in Crohn's disease
1. Relapse 2. Treatment Failure
outcomes:
Mobile phone‐based interventions for improving contraception use
1. Motor Vehicle Traffic Accident 2. IUD contraception 3. Medication Action/side Effects Care 4. Pregnancy 5. Contraception
outcomes:
Infant isolation and cohorting for preventing or reducing transmission of healthcare‐associated infections in neonatal units
1. Healthcare associated infectious disease
outcomes:
Oral contraceptives containing drospirenone for premenstrual syndrome
1. Premenstrual Symptom 2. Adverse Event
outcomes:
Opioids for procedural pain in neonates
1. Acute Pain in Newborn Infants 2. Apnea 3. Pain 4. Pulse Rate - Bradycardia 5. Bernese Pain Scale for Neonates 6. ABC Scale 7. Neonatal Infant Pain Scale 8. Douleur Aigue du Nouveau-ne 9. Low Blood Pressure 10. Premature Infant Pain Profile 11. Behavioural Indicators of Infant Pain 12. Neonatal, Pain, Agitation and Sedation Scale
outcomes:
Oral stimulation for promoting oral feeding in preterm infants
1. Intravenous Feeding Of Patient 2. Length of ICU Stay 3. Length Of Stay 4. Total Parenteral Nutrition 5. Infant Feeding Method
outcomes:
Pentoxifylline for treatment of sepsis and necrotising enterocolitis in neonates
1. Chronic Lung Disease 2. Intraventricular Hemorrhage 3. Retinopathy Of Prematurity 4. Necrotizing Enterocolitis 5. Periventricular Leukomalacia 6. Death 7. Hospitalization
outcomes:
Routine monitoring of gastric residual for prevention of necrotising enterocolitis in preterm infants
1. All Cause Mortality 2. Enteral nutrition 3. Extrauterine growth restriction 4. Necrotizing Enterocolitis 5. Total Parenteral Nutrition 6. Weight Gain 7. Feeding Problems In Newborn
outcomes:
Nebulised hypertonic saline for cystic fibrosis
1. Forced Expiratory Volume 1 2. Forced Vital Capacity 3. Cystic Fibrosis Pulmonary Exacerbation 4. Forced Expiratory Volume 5. Finding Related To Ability To Clear Sputum 6. Death 7. Lung function test 8. Adverse Event
outcomes:
Non‐pharmacological management of infant and young child procedural pain
1. Pain 2. Distress 3. Pain Relief
outcomes:
Antivirals for prevention of hepatitis B virus mother‐to‐child transmission in human immunodeficiency virus positive pregnant women co‐infected with hepatitis B virus
1. Infant Death 2. Serious Adverse Event 3. Maternal Death 4. Hepatitis B
outcomes:
Hand hygiene for the prevention of infections in neonates
1. Infection 2. Late Neonatal Death 3. Early Neonatal Death
outcomes:
Comparative effectiveness of psychological interventions for treating the psychological consequences of sexual abuse in children and adolescents: a network meta‐analysis
1. Self-harm 2. Behavior 3. Posttraumatic Stress Disorder 4. Quality of Life 5. Depression 6. Anxiety 7. Social functioning
outcomes:
Alemtuzumab for multiple sclerosis
1. Relapse 2. Disease Progression 3. Adverse Event 4. Expanded Disability Status Scale
outcomes:
Interventions for the symptoms and signs resulting from jellyfish stings
1. Pain 2. Adverse Event
outcomes:
Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
1. Body Mass Index 2. Forced Vital Capacity 3. Growth 4. Body weight 5. Nutritional Finding 6. Time-to-Event 7. Infection due to Pseudomonas Aeruginosa 8. Cough 9. Weight change 10. Serious Adverse Event 11. Forced Expiratory Volume 12. Height and growth measurements 13. Infective Pulmonary Exacerbation Of Cystic Fibrosis 14. Withdrawal Due To Adverse Events 15. Respiratory Tract Infection
outcomes:
Acetylcholinesterase inhibitors for autistic spectrum disorders
1. Social Interaction 2. Communication skills 3. Feeling Irritable 4. Fatigue 5. Repetitious Behavior 6. Adverse Event
outcomes:
Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review
1. Time to clinical improvement 2. All Cause Mortality 3. Serious Adverse Event 4. Disease Progression 5. Adverse Event 6. Clinical Improvement
outcomes:
Prebiotics to prevent necrotising enterocolitis in very preterm or very low birth weight infants
1. All Cause Mortality 2. Necrotizing Enterocolitis
outcomes:
Lactoferrin for the postoperative management of term neonates after gastrointestinal surgery
1. Infection 2. Death
outcomes:
Videolaryngoscopy versus direct laryngoscopy for tracheal intubation in neonates
1. Airway Trauma 2. Intubation 3. Adverse Event
outcomes:
Nasal high flow therapy for primary respiratory support in preterm infants
1. Bronchopulmonary Dysplasia Of Newborn 2. Death 3. Mechanical ventilation
outcomes:
Conventional chest physiotherapy compared to other airway clearance techniques for cystic fibrosis
1. Respiratory exacerbation 2. Lung function test
outcomes:
Antiseptic solutions for skin preparation during central catheter insertion in neonates
1. Central Venous Catheter Associated Bloodstream Infection 2. Clinical Sepsis
outcomes:
Personalised interventions for subgroups of children with conduct problems
1. Behavior
outcomes:
Fecal transplantation for treatment of inflammatory bowel disease
1. Relapse 2. Crohn's Disease In Remission 3. Ulcerative Colitis In Remission 4. Serious Adverse Event 5. Remission 6. Adverse Event 7. Therapeutic Response
outcomes:
Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents
1. Attention Deficit Hyperactivity Disorder
outcomes:
Airway clearance techniques compared to no airway clearance techniques for cystic fibrosis
1. Forced Expiratory Volume 1 2. Forced Vital Capacity 3. Mucus Discharge 4. Lung function test 5. Expectoration
outcomes:
Systemic opioid regimens for postoperative pain in neonates
1. Comfort Scale 2. Cognitive Developmental Delay 3. Bayley Scale Of Infant Development 4. Intellect Impaired 5. Neonatal Infant Pain Scale 6. Visual Analog Scale 7. Griffiths Mental Developmental Scale 8. Neonatal, Pain, Agitation and Sedation Scale 9. Sensorineural Hearing Loss 10. Pain 11. Blindness 12. Death 13. Child Development 14. Premature Infant Pain Profile
outcomes:
Nebulised hypertonic saline solution for acute bronchiolitis in infants
1. Hospital discharge 2. Tachycardia 3. Tremor 4. Vomiting 5. Pallor 6. Hospitalization 7. Nausea 8. Diarrhoea 9. Acute Retention Of Urine 10. Hypertensive disorder 11. Clinical Improvement
outcomes:
Non‐opioid analgesics for procedural pain in neonates
1. Apnea 2. Pain 3. Bernese Pain Scale for Neonates 4. ABC Scale 5. Neonatal Infant Pain Scale 6. Douleur Aigue du Nouveau-ne 7. Neonatal Bradycardia 8. Low Blood Pressure 9. Premature Infant Pain Profile 10. Behavioural Indicators of Infant Pain 11. Neonatal, Pain, Agitation and Sedation Scale
outcomes:
Chest physiotherapy for acute bronchiolitis in paediatric patients between 0 and 24 months old
1. Adverse Event 2. Time-to-Event 3. Clinical Improvement 4. Bronchiolitis
outcomes:
Bubble devices versus other pressure sources for nasal continuous positive airway pressure in preterm infants
1. Apnea 2. Death 3. Hypoxia 4. Neurodevelopmental Disorder 5. Mechanical ventilation 6. Oxygen Therapy
outcomes:
Zinc supplementation for preventing mortality, morbidity, and growth failure in children aged 6 months to 12 years
1. Lower Respiratory Tract Infection 2. Vomiting 3. Death 4. Diarrhoea
outcomes:
Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
1. Attention Deficit Hyperactivity Disorder 2. Adverse Event
outcomes:
Postnatal phenobarbital for the prevention of intraventricular haemorrhage in preterm infants
1. Ventricular Dilatation 2. Intraventricular Hemorrhage 3. Hydrocephalus 4. Death 5. Neurodevelopmental Disorder
outcomes:
Botulinum toxin for the treatment of strabismus
1. Fusion With Defective Stereopsis 2. Binocular Single Vision 3. Adverse Event
outcomes:
Systemic corticosteroid regimens for prevention of bronchopulmonary dysplasia in preterm infants
1. Bronchopulmonary Dysplasia Of Newborn 2. Death 3. Cerebral Palsy 4. Neurodevelopmental Delay
outcomes:
Medical interventions for traumatic hyphema
1. Hyphema 2. Visual Acuity Testing
outcomes:
Ultrasound‐guided arterial cannulation in the paediatric population
1. Treatment Success 2. Arterial Cannula Insertion
outcomes:
Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis
1. Body Mass Index 2. Forced Vital Capacity 3. Growth 4. Cystic Fibrosis Pulmonary Exacerbation 5. Respiratory Function 6. Oropharyngeal pain 7. Nutritional Finding 8. Adverse Event 9. Weight change 10. Serious Adverse Event 11. Forced Expiratory Volume 12. Quality of Life 13. Death 14. Height and growth measurements 15. Kidney injury 16. Sweat Finding
outcomes:
Systemic opioids versus other analgesics and sedatives for postoperative pain in neonates
1. Cognitive function 2. Pain 3. Education 4. Death 5. Neurodevelopmental Disorder 6. Neurodevelopmental Delay
outcomes:
Interventions for preventing and treating kidney disease in IgA vasculitis
1. Kidney disease 2. Infection 3. Leukopenia 4. Decreased Renal Function 5. Haemorrhage 6. Hypertensive disorder 7. Proteinuria
outcomes:
Catheter insertion techniques for improving catheter function and clinical outcomes in peritoneal dialysis patients
1. Disorder Of Peritoneal Dialysis Catheter 2. Peritoneal Dialysis 3. Treatment Failure 4. Death
outcomes:
Probiotics for management of functional abdominal pain disorders in children
1. Pain 2. Treatment Success
outcomes:
Stem cell‐based interventions for the prevention and treatment of intraventricular haemorrhage and encephalopathy of prematurity in preterm infants
1. All Cause Mortality 2. Sensorineural Hearing Loss 3. Intraventricular Hemorrhage 4. Intellect Impaired 5. Blindness 6. Developmental Delay 7. Cerebral Palsy 8. Neurodevelopmental Delay
outcomes:
Antibiotics for chronic pulmonary infection in children with a neurodisability (neurodevelopmental disorder)
1. Quality of Life 2. Respiratory exacerbation 3. Hospitalization 4. Time-to-Event 5. Patient-Reported Outcome
outcomes:
Behavioural and cognitive‐behavioural interventions for outwardly directed aggressive behaviour in people with intellectual disabilities
1. Assessment Of Quality Of Life 2. Finding Related To Ability To Control Anger 3. Aggressive Behavior 4. Mental State Finding
outcomes:
Vitamin D for the management of asthma
1. Forced Expiratory Volume 1 2. Serious Adverse Event 3. Emergency Department Patient Visit 4. Hospitalization 5. Asthma Control 6. Asthma-Related Death 7. Asthma exacerbation 8. Asthma Control Test
outcomes:
Active cycle of breathing technique for cystic fibrosis
1. Quality of Life 2. Death 3. Patient Satisfaction
outcomes:
Physical interventions to interrupt or reduce the spread of respiratory viruses
1. Viral Respiratory Infection 2. Adverse Event
outcomes:
Surgical versus non‐surgical interventions for treating patellar dislocation
1. Recurrent Dislocation Of Knee 2. Functional ability 3. Adverse Event
outcomes:
Vitamin D as an adjunct to antibiotics for the treatment of acute childhood pneumonia
1. Community Acquired Pneumonia 2. Death 3. Clinical Resolution 4. Duration Of Hospital Stay 5. Hospitalization 6. Time-to-Event
outcomes:
Bisphosphonates for osteoporosis in people with cystic fibrosis
1. Fracture
outcomes:
Glucocorticoids for croup in children
1. Hospitalization 2. Adverse Event 3. Croup
outcomes:
Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants
1. Disability 2. All Cause Mortality 3. Treatment Failure 4. Serum Creatinine 5. Death 6. Occult Blood In Stools 7. Patent Ductus Arteriosus 8. Neurodevelopmental Delay 9. Gastrointestinal Bleeding
outcomes:
Late (≥ 7 days) inhaled corticosteroids to reduce bronchopulmonary dysplasia in preterm infants
1. Bronchopulmonary Dysplasia Of Newborn 2. Death 3. Dependence On Supplemental Oxygen 4. Neonatal Death
outcomes:
Vaccines for the common cold
1. Adverse Drug Reaction 2. Death 3. Common Cold 4. Adverse Event
outcomes:
Homeopathic medicinal products for preventing and treating acute respiratory tract infections in children
1. Duration of Symptom 2. Employee absenteeism 3. Acute Respiratory Tract Infection 4. Disease Recurrence 5. Quality of Life 6. Clinical Resolution 7. Hospitalization 8. Adverse Event 9. Antibiotic Therapy 10. Clinical Improvement
outcomes:
Interventions for the eradication of meticillin‐resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis
1. Forced Expiratory Volume 1 2. Methicillin Resistant Staphylococcus Aureus Positive 3. Growth 4. Lung function test 5. Infective Pulmonary Exacerbation Of Cystic Fibrosis 6. Adverse Event 7. Time-to-Event 8. Nutritional status 9. Therapeutic Response 10. Methicillin Resistant Staphylococcus Aureus Infection
outcomes:
Family‐centred interventions for Indigenous early childhood well‐being by primary healthcare services
1. Decreased Alcohol Consumption 2. General well-being 3. Smoking Reduced 4. Lifestyle 5. Child Development 6. General Physical Finding 7. Parenting 8. Health Behavior 9. Adverse Event 10. Substance Misuse Decreased
outcomes:
Ultrasound guidance versus landmark method for peripheral venous cannulation in adults
1. Pain 2. Insertion Success
outcomes:
Bioengineered nerve conduits and wraps for peripheral nerve repair of the upper limb
1. Medical Research Council Motor Power Scale 2. Upper Limb Function 3. Costs and Cost Analysis 4. Sensory Testing 5. Disability Of Arm 6. Sensory Nerve Conduction Study 7. Muscle Strength 8. Disabilities Of The Arm, Shoulder And Hand Outcome Measurement
outcomes:
Statins for Smith‐Lemli‐Opitz syndrome
1. Neurological Findings Abnormal 2. Overall Survival 3. Smith-lemli-opitz Syndrome 4. Death 5. Statin Prophylaxis